Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Sarcoma 1

Conditions

Sarcoma 22Melanoma 6Histiocytoma, Malignant Fibrous 6Gastrointestinal Stromal Tumors 5Osteosarcoma 4Neoplasm Metastasis 4Gliosarcoma 4Neuroblastoma 3Hemangiosarcoma 3Chordoma 3Bone Neoplasms 3Wilms Tumor 2Triple Negative Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma 2Lung Neoplasms 2Liver Neoplasms 2Liposarcoma 2Head and Neck Neoplasms 2Glioblastoma 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Bile Duct Neoplasms 2

Interventions

Temozolomide 51Bevacizumab 23Radiotherapy 16Magnetic Resonance Spectroscopy 16Irinotecan 15Carmustine 12Erlotinib Hydrochloride 10Carboplatin 8Surgical Procedures, Operative 6O(6)-benzylguanine 6Imatinib Mesylate 6Filgrastim 6Cyclophosphamide 6Biopsy 6sargramostim 5aldesleukin 5X-Rays 5Thalidomide 5Phantoms, Imaging 5Chemotherapy, Adjuvant 52-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 5temsirolimus 4Topotecan 4Specimen Handling 4Sirolimus 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Nuclear Medicine Department, Hospital 4Etoposide 4Cisplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Ipilimumab × Sarcoma × Clear all
NCT04817254 2026-04-17

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
47 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡